The apelin receptor (APJ) is a membrane protein expressed in cells of many organs, particularly the brain, the cardiovascular system, and the kidneys. It is a potential therapeutic target for cardiovascular diseases and water imbalances.
APJ belongs to the large family of G protein-coupled receptors (GPCRs) and, like other GPCRs, consists of seven transmembrane segments and several extracellular and intracellular loops.
Two endogenous ligands of this receptor have been identified: apelin and elabela; they bind to it differently, although the molecular bases for this are not clearly identified.
In an article published in the British Journal of Pharmacology, researchers from the Laboratory of Experimental and Molecular Pharmacology (LPEM, SIMoS/DMTS) highlight that a disulfide bridge differentially regulates the binding of apelin and elabela to the receptor, and that the disruption of this bridge considerably reduces apelin-dependent signaling but not elabela-dependent signaling. This disulfide bridge, which links the N-terminal part and the third extracellular loop, forms a structural constraint analogous to a fourth extracellular loop, as in chemokine receptors, involved in the activation of immune cells.
Further studies are needed to determine if apelin fragments can play the same role as chemokines and if APJ can be considered a member of the chemokine receptor family.
Contact at the Frédéric-Joliot Institute for Life sciences:
Text translated with the help of Vibe from Meta AI.